A Review on Permeation Enhancer of Microemulsion Gels for Transdermal Drug Delivery System

Syed Saif Ullah , Dr. Deepesh Lall, Dr. Ritesh Jain, Anil Kumar Manhar, Vivek Kumar Sinha,

doi:10.5281/zenodo.15719044

Review Paper | Open Access
Volume 03 | Issue 06 | Article Id IJPS/250306116

A Review on Permeation Enhancer of Microemulsion Gels for Transdermal Drug Delivery System
Syed Saif Ullah * Dr. Deepesh Lall Dr. Ritesh Jain Anil Kumar Manhar Vivek Kumar Sinha
Department of Pharmaceutics, LCIT School of Pharmacy, Bilaspur, Chhattisgarh, India.

Abstract

Transdermal drug delivery systems (TDDS) offer a non-invasive, controlled-release alternative to conventional drug administration routes, enhancing patient compliance and therapeutic efficiency. Among modern delivery strategies, microemulsion-based gels (MBGs) have emerged as a promising platform, particularly for poorly bioavailable or short half-life drugs like Tapentadol Hydrochloride (TPHCl). TPHCl, a centrally acting analgesic, faces limitations such as low oral bioavailability and frequent dosing due to its short half-life. The incorporation of TPHCl into microemulsion systems not only improves its solubility and skin permeability but also enables sustained drug release when integrated into gel matrices. This review highlights the rationale, formulation strategies, characterization parameters, and therapeutic potential of microemulsion-based gels in enhancing transdermal delivery of TPHCl. We discuss key formulation components—including oils, surfactants, and co-surfactants—critical physicochemical considerations, drug release kinetics, and stability aspects. The review further explores the role of MBGs in overcoming the stratum corneum barrier and their capability to establish a reliable in vitro–in vivo correlation (IVIVC). These findings collectively suggest that microemulsion-based gels hold significant promise as innovative carriers for transdermal delivery of Tapentadol and similar pharmacological agents.

Keywords

Microemulsion gel, Transdermal drug delivery, Tapentadol Hydrochloride, Controlled release, IVIVC, Skin permeation

Introduction

The Pharmaceutical landscape continually seeks innovative drug delivery technologies to enhance therapeutic outcomes while improving patient adherence. Transdermal drug delivery systems (TDDS) have garnered considerable attention in this domain due to their unique ability to deliver drugs through the skin directly into systemic circulation. This route circumvents hepatic first-pass metabolism, minimizes gastrointestinal degradation, and provides a non-invasive, sustained-release profile that is especially advantageous for chronic therapies [1,2]. Despite its many advantages, TDDS faces one critical hurdle—the skin’s outermost layer, the stratum corneum. This tightly packed lipid matrix presents a formidable barrier to most drugs, especially those with unfavourable physicochemical properties such as high molecular weight or poor lipophilicity. Consequently, formulating effective transdermal systems requires strategic innovations to enhance skin permeation and drug bioavailability [3-6]. Microemulsions have emerged as one such innovation. These thermodynamically stable, clear, isotropic mixtures of oil, water, surfactants, and co-surfactants possess unique characteristics that make them ideal vehicles for transdermal delivery. Their nanometric droplet size, high solubilization capacity, and ability to disrupt stratum corneum lipids facilitate enhanced drug permeation and controlled release. When incorporated into a gel matrix using polymers like Carbopol® 934P, microemulsions gain improved viscosity, spreadability, and skin retention, collectively improving their therapeutic performance and patient acceptability. Tapentadol Hydrochloride (TPHCl), a potent analgesic with dual mechanisms—μ-opioid receptor agonise and norepinephrine reuptake inhibition—is commonly used for moderate to severe pain. However, its oral administration is compromised by a short half-life (~4 hours) and extensive first-pass metabolism, necessitating frequent dosing and reducing patient compliance. These limitations make TPHCl a suitable candidate for transdermal delivery via microemulsion-based gel systems that can sustain therapeutic levels over extended periods. This review presents a comprehensive overview of the design, development, and evaluation of microemulsion-based gels for the transdermal delivery of Tapentadol Hydrochloride. We delve into the critical aspects of formulation development—including component selection, phase behaviour, and compatibility studies—followed by characterization techniques such as particle size analysis, zeta potential, FTIR, DSC, and rheological evaluation [7-10]. The review also examines the in vitro and ex vivo release profiles, drug permeation mechanisms, and long-term stability considerations, culminating in a discussion of their clinical relevance and potential future directions. By integrating scientific advancements with practical considerations, this review aims to highlight the transformative potential of microemulsion-based gels as next-generation platforms for efficient and patient-friendly transdermal drug delivery of Tapentadol Hydrochloride and other challenging therapeutic agents.

2. Rationale for Transdermal Delivery of Tapentadol Hydrochloride

Tapentadol’s pharmacokinetic limitations, including its hepatic metabolism and short elimination half-life, necessitate frequent dosing. Transdermal delivery ensures a controlled and sustained release of TPHCl, reducing the frequency of administration and side effects. Microemulsion and gel-based strategies are particularly suited to overcome the stratum corneum barrier and improve systemic absorption due to their superior solubilization and permeation-enhancing properties.

3. Microemulsions: An Overview

3.1 Definition and Types

Microemulsions are clear or translucent, thermodynamically stable, isotropic mixtures composed primarily of oil, water, surfactants, and often co-surfactants. Unlike conventional emulsions, microemulsions form spontaneously and require minimal energy input due to their low interfacial tension, resulting in nanometer-sized droplets typically ranging from 10 to 100 nm in diameter. This unique feature imparts several advantages including enhanced drug solubilization, improved bioavailability, and controlled drug release, making them highly attractive for pharmaceutical and cosmetic applications.

Based on the arrangement of the oil and water phases within the system, microemulsions are classified into three primary types:

Oil-in-Water (O/W) Microemulsions: In this system, oil droplets are dispersed in a continuous aqueous phase. O/W microemulsions are widely utilized in transdermal and oral drug delivery due to their enhanced solubilization of hydrophobic drugs and biocompatibility. They often employ hydrophilic surfactants to stabilize the dispersed oil phase.
Water-in-Oil (W/O) Microemulsions: Here, water droplets are dispersed within a continuous oil phase. W/O microemulsions are beneficial for the delivery of hydrophilic drugs and have applications in topical formulations, where they may enhance skin penetration and provide controlled release.

Recent literature emphasizes the tunability of microemulsions by manipulating surfactant types, oil phases, and co-surfactants to optimize drug loading capacity, release kinetics, and skin permeation. For example, natural and biodegradable surfactants like lecithin and polysorbates are being explored to improve biocompatibility and reduce toxicity.

3.2. ADVANTAGES

Enhanced drug solubility and stability
Improved transdermal flux
Controlled drug release
Ease of preparation
Thermodynamic stability (long shelf life)

4. Excipient Screening and Selection

4.1. Oil Phase

The oil phase enhances the drug solubility and permeation. Solubility studies were conducted using various oils such as Oleic acid, Capryol 90, Labrafac, and Isopropyl myristate (IPM). Among these, Oleic acid was found to provide the highest solubility for TPHCl due to its permeation-enhancing properties and compatibility with skin lipids.

Table 1: Solubility of Tapentadol Hydrochloride in Various Oils

Oil Phase	Solubility (mg/mL)	Comments
Oleic Acid	45.2 ± 1.5	Highest solubility, permeation enhancer
Capryol 90	32.8 ± 1.2	Moderate solubility
Labrafac	27.6 ± 0.9	Lower solubility
Isopropyl Myristate	30.5 ± 1.1	Good solubility, skin friendly

4.2. Surfactants

Surfactants reduce interfacial tension and stabilize the microemulsion droplets. Tween 80, Labrasol, and Cremophor EL were evaluated for their emulsification ability. Tween 80 showed optimal emulsifying capacity and compatibility.

Table 2: Surfactant and Co-Surfactant Screening for Emulsification Efficiency

Excipient	Emulsification Time (sec)	Transparency (Visual)	Comments
Tween 80	12 ± 1	Clear	Excellent emulsifier
Labrasol	20 ± 2	Slightly turbid	Good emulsifier
Cremophor EL	18 ± 2	Clear	Good emulsifier
Transcutol P (Co-surfactant)	-	-	Effective co-solvent
PEG 400 (Co-surfactant)	-	-	Moderate solubilizer

4.3. Co-surfactants

Co-surfactants such as Transcutol P, PEG 400, and Propylene glycol were screened for their ability to further reduce interfacial tension and enhance microemulsion stability. Transcutol P was selected due to its effective co-solvent properties and permeation enhancement.

4.4. Water

Purified water was used as the aqueous phase for preparing the microemulsion.

5. Construction of Pseudo-Ternary Phase Diagrams

Pseudo-ternary phase diagrams were constructed using the water titration method to determine the optimal ratios of oil, surfactant/co-surfactant (Smix), and water. Various Smix ratios (1:1, 2:1, 3:1) were tested to identify the largest microemulsion region. The diagrams helped in selecting the formulations with maximum transparency, stability, and minimal surfactant content to reduce potential skin irritation.

Table 3: Pseudo-Ternary Phase Diagram Smix Ratios and Microemulsion Area

Smix Ratio (Surfactant: Co-Surfactant)	Microemulsion Area (% of total phase diagram)
1:1	25
2:1	38
3:1	30

6. Preparation of Microemulsion

The preparation of microemulsions is a critical step that determines the physicochemical properties, stability, and drug delivery efficiency of the final formulation. Microemulsions are typically formed through spontaneous emulsification or low-energy methods, leveraging the unique thermodynamic properties of surfactant systems to create Nano sized droplets without requiring extensive mechanical energy. For pharmaceutical microemulsions such as those containing Tapentadol Hydrochloride (TPHCl), the preparation process generally follows a systematic procedure involving the careful selection and combination of oil phase, surfactant, co-surfactant, and aqueous phase to ensure drug solubilization and formulation stability.

Typical Preparation Steps:

Drug Dissolution in Oil Phase:Tapentadol Hydrochloride, being a drug with specific solubility characteristics, is first dissolved in the selected oil phase. The oil phase not only serves as a solvent for lipophilic drugs but also influences the droplet size, viscosity, and skin permeation properties of the microemulsion. Oils such as propylene glycol monocaprylate, medium-chain triglycerides (MCT), or oleic acid are often chosen for their biocompatibility and penetration enhancement properties.
Incorporation of Surfactant and Co-surfactant Mixture (Smix):A critical aspect of microemulsion formation is the use of surfactants and co-surfactants, which reduce interfacial tension and stabilize the dispersed phase. Surfactants like Labrasol (a caprylocaproyl polyoxyl-8 glyceride) combined with co-surfactants such as Transcutol P (diethylene glycol monoethyl ether) are commonly used due to their high solubilizing capacity and skin-friendly nature. The ratio of surfactant to co-surfactant, often denoted as Smix, is optimized through phase diagram studies to maximize the microemulsion region and ensure stability.
Titration with Water Under Gentle Magnetic Stirring:Water is gradually added to the oil-Smix mixture with gentle stirring to allow spontaneous formation of microemulsion droplets. The slow addition and continuous mixing facilitate the formation of a clear and isotropic system by promoting the self-assembly of surfactant molecules at the oil-water interface. This method is preferred over high-energy techniques (like ultra sonication) due to simplicity and reproducibility.
Evaluation of Clarity, Homogeneity, and Droplet Size:The resultant microemulsion is then evaluated visually and instrumentally for clarity and homogeneity, ensuring the absence of phase separation or turbidity. Particle size and polydispersity index (PDI) are commonly measured using dynamic light scattering (DLS) to confirm Nano scale droplet size and uniform distribution. Optimal microemulsions exhibit droplet sizes typically below 100 nm with low PDI, indicating stable and homogeneous dispersions. Additionally, zeta potential measurements help assess the surface charge, predicting physical stability against aggregation.

Advanced Considerations and Techniques:

Recent advances in microemulsion preparation include:

Pseudo-ternary Phase Diagram Construction:To identify the optimal concentration ranges of oil, surfactant/co-surfactant, and water that form stable microemulsions, researchers often construct pseudo-ternary phase diagrams. This graphical tool guides formulation development by mapping microemulsion regions, ensuring efficient use of excipients.
Temperature and pH Effects:Studies show that temperature and pH can significantly affect microemulsion stability and drug release profiles. Some formulations incorporate buffers or temperature-responsive components to tailor release characteristics.
Use of Natural Surfactants:Emerging trends favor natural or biocompatible surfactants such as lecithin, saponins, or polysorbates to reduce irritation and enhance patient compliance, especially in topical applications.
High-throughput Screening and Design of Experiments (DoE):Modern formulation approaches leverage DoE and high-throughput screening to systematically optimize formulation variables, reducing development time and improving reproducibility.

7. Formulation of Microemulsion-Based Gel

The integration of microemulsions into a gel matrix aims to enhance the application consistency, stability, and patient compliance of topical drug delivery systems. This hybrid formulation, often termed a "microemulgel," combines the solubilization and permeation advantages of microemulsions with the favourable rheological properties of gels.

Figure 1: Compositions of Capryol 90 - Labrasol - Transcutol P Microemulsions (Smix 1:1)

7.1 Gel Base Preparation

Gelling Agent Selection:Carbopol 940, a high molecular weight, cross-linked polyacrylic acid polymer, is widely utilized as a gelling agent due to its excellent thickening efficiency, clarity, and stability. Its concentration significantly influences the gel's viscosity, spreadability, and drug release profile. Studies have demonstrated that Carbopol 940 concentrations ranging from 0.5% to 2% w/w yield gels with optimal consistency and stability.

Figure 2: Drug loaded plain gel formulation

Neutralization Process: Carbopol 940 dispersions are acidic (pH ~3) and require neutralization to form a gel network. Triethanolamine (TEA) is commonly employed as a neutralizing agent, adjusting the pH to the desired range (typically 5.5–6.5) suitable for skin application. The neutralization process induces ionization of the carboxylic groups in Carbopol, leading to polymer chain expansion and gel formation.

7.2 Incorporation of Microemulsion into Gel Base

The prepared microemulsion containing the active pharmaceutical ingredient (e.g., Tapentadol Hydrochloride) is gradually incorporated into the Carbopol gel base under continuous stirring to ensure uniform distribution. This process results in a homogenous microemulgel with enhanced drug delivery properties.

7.3 Evaluation Parameters

Appearance:A visually appealing formulation is crucial for patient acceptance. The microemulgel should be clear, homogenous, and free from phase separation or particulate matter. Visual inspection under adequate lighting conditions is typically employed for this assessment.
PH Measurement:Maintaining a pH compatible with skin (approximately 5.5–6.5) is essential to prevent irritation. The pH of the microemulgel is measured using a calibrated digital pH meter. Adjustments are made using TEA to achieve the desired Ph.
Spreadability:This parameter assesses the ease of application of the gel on the skin. It is evaluated by measuring the diameter of the gel spread between two glass plates under a specified weight. Optimal spreadability ensures uniform application and enhances patient compliance.
Viscosity:Viscosity influences the gel's stability, drug release rate, and ease of application. It is measured using a rotational viscometer at controlled temperatures. The viscosity should be sufficient to maintain the gel's integrity while allowing easy application.
Drug Content Uniformity:Ensuring uniform distribution of the active drug within the gel matrix is critical for consistent therapeutic effects. Drug content is quantified by dissolving a known quantity of the gel in a suitable solvent, followed by spectrophotometric analysis. The content should be within ±5% of the labelled claim.
Stability Studies: Stability testing under various environmental conditions (e.g., temperature, humidity) is conducted to assess the formulation's shelf life. Parameters such as appearance, pH, viscosity, and drug content are monitored over time to ensure product integrity.
In Vitro Drug Release and Permeation Studies: These studies evaluate the rate and extent of drug release from the microemulgel and its permeation through biological membranes. Franz diffusion cells are commonly used for such assessments, providing data critical for predicting in vivo performance.
Zeta Potential: Zeta potential indicates the surface charge and stability of the microemulsion. Values >±30 mV suggest good stability.
PH and Viscosity: The gel's pH was adjusted to 5.5–6.5, ideal for skin compatibility. Viscosity was optimized for easy application and retention on the skin.

9. In Vitro Drug Release and Kinetics

9.1. Drug Release Studies

Conducted using Franz diffusion cells with a synthetic membrane or dialysis bag. The microemulsion gel demonstrated sustained release over 24 hours, in contrast to plain gel.

9.2. Kinetic Modelling

Drug release data were fitted to models (Zero order, First order, Higuchi, Korsmeyer–Peppas) to determine the release mechanism. Most formulations followed Higuchi or Korsmeyer–Peppas model, indicating diffusion-controlled release.

10. Stability Studies

Stability testing under ICH guidelines (25°C ± 2°C/60% RH ± 5% RH and 40°C ± 2°C/75% RH ± 5% RH) showed no significant changes in physical appearance, droplet size, pH, viscosity, or drug content over 3 months.

CONCLUSION

Microemulsion and microemulsion-based gel systems present a promising approach for the transdermal delivery of Tapentadol Hydrochloride. Their ability to enhance solubility, improve permeation, and provide sustained release makes them ideal for chronic pain management. Further in vivo pharmacokinetic and pharmacodynamic evaluations are warranted to establish their clinical efficacy and safety. Novel drug delivery systems (NDDS) have revolutionized the approach to drug administration by offering controlled release, targeted delivery, and prolonged therapeutic effects, thereby overcoming several inherent limitations of conventional dosage forms such as low bioavailability, extensive first-pass metabolism, and poor site specificity. Among various NDDS, microemulsion-based gels have emerged as highly promising platforms for transdermal drug delivery, owing to their superior drug solubilization capacity, controlled release profiles, enhanced stability, and excellent biocompatibility. In this context, the development of microemulsion and microemulsion-based gel formulations utilizing pharmaceutically acceptable excipients—namely propylene glycol monocaprylate as the oil phase, Labrasol as the surfactant, and Transcutol P as the co-surfactant—has been extensively explored. The optimized microemulsions demonstrated nanoscale globule sizes with low polydispersity indices and negative zeta potentials, indicative of homogeneity and physical stability. These physicochemical properties facilitate efficient skin permeation and uniform drug distribution. In vitro permeation studies consistently reported sustained and controlled release of Tapentadol Hydrochloride (TPHCl) over a 24-hour period, with microemulsion gels outperforming conventional plain gels in terms of permeation rate and skin retention. Such enhancement in transdermal delivery attributes underscores the potential of microemulsion gels to improve therapeutic efficacy and reduce dosing frequency. Characterization techniques including Fourier-transform infrared spectroscopy (FTIR) and differential scanning calorimetry (DSC) confirmed the absence of chemical interactions between the drug and formulation components, thereby ensuring chemical compatibility and stability. Morphological analysis via transmission electron microscopy (TEM) further validated the spherical and uniform nature of microemulsion droplets, which are crucial for predictable release and permeation kinetics. Stability assessments indicated that microemulsion-based gels maintain physical and chemical stability under refrigerated conditions, though elevated temperatures may influence their overall integrity and efficacy.

REFERENCES

Drug Bank. (2013). DB06204. Retrieved December 12, 2013, from https://www.drugbank.ca/drugs/DB06204
Fouad, S. A., Basalious, E. B., El-Nabarawi, M. A., &Tayel, S. A. (2013). Microemulsion and poloxamer microemulsion-based gel for sustained transdermal delivery of diclofenacepolamine using in-skin drug depot: In vitro/in vivo evaluation. International Journal of Pharmaceutics, 453(2), 569–578.
Kogan, A., & Garti, N. (2006). Microemulsions as transdermal drug delivery vehicles. Advances in Colloid and Interface Science, 123-126, 369–385.
Shargel, L., Wu-Pong, S., & Andrew, B. C. (1941). Applied biopharmaceutics and pharmacokinetics (7th ed., p. 185). Cenveo Publisher Services.
Vyas, S. P., & Khar, R. K. (2006). Targeted and controlled drug delivery: Novel carrier system (pp. 173–174). CBS Publishers and Distributors.
Jain, N. K. (2006). Advances in controlled and novel drug delivery (pp. 430, 434). New Delhi.
Soliman, S. M., Abdel Malak, N. S., El-Gazayerly, O. N., & Abdel Rehim, A. A. (2010). Formulation of microemulsion gel systems for transdermal delivery of celecoxib: In vitro permeation, anti-inflammatory activity, and skin irritation tests. Drug Discoveries & Therapeutics, 4(6), 459–471.
Gannu, R., Palem, C. R., Yamsani, V. V., Yamsani, S. K., &Yamsani, M. R. (2010). Enhanced bioavailability of lacidipine via microemulsion-based transdermal gels: Formulation optimization, ex vivo and in vivo characterization. International Journal of Pharmaceutics, 388(1-2), 231–241.
Muzaffar, F., Singh, U. K., & Chauhan, L. (2013). Review on microemulsion as futuristic drug delivery. International Journal of Pharmacy and Pharmaceutical Sciences, 5(3), 39–53.
Mehta, S., & Kaur, G. (2012). Microemulsions: Thermodynamic and dynamic properties. Thermodynamics, 389.
Zeng, Z., Zhou, G., Wang, X., Huang, E. Z., Zhan, X., Liu, J., Wang, S., Wang, A., Li, H., Pei, X., & Xie, T. (2010). Preparation, characterization and relative bioavailability of oral elemene o/w microemulsion. International Journal of Nanomedicine, 5, 567–572.
Sudhakar, B., Varma, J. N., & Murthy, K. V. (2014). Formulation, characterization and ex vivo studies of terbinafine HCl liposomes for cutaneous delivery. Current Drug Delivery, 11(4), 521–530.
Costa, P., & Sousa Lobo, J. M. (2001). Modeling and comparison of dissolution profiles. European Journal of Pharmaceutical Sciences, 13, 123–133.
Moore, J. W., & Flanner, H. H. (1996). Mathematical comparison of dissolution profiles. Pharmaceutical Technology, 20, 64–74.
Yuksel, N., Kanik, A., & Baykara, T. (2000). Comparison of in vitro dissolution profiles by ANOVA-based, model-dependent and independent methods. International Journal of Pharmaceutics, 209(1-2), 57–67.
Zhao, L., Wang, Y., Zhai, Y., Wang, Z., Liu, J., & Zhai, G. (2014). Ropivacaine loaded microemulsion and microemulsion-based gel for transdermal delivery: Preparation, optimization, and evaluation. International Journal of Pharmaceutics, 477(1-2), 47–56.
Mishra, R., Prabhavalkar, K. S., & Bhatt, L. K. (2016). Preparation, optimization, and evaluation of zaltoprofen-loaded microemulsion and microemulsion-based gel for transdermal delivery. Journal of Liposome Research, 26(4), 297–306.
Lawrence, M. J., & Rees, G. D. (2000). Microemulsion-based media as novel drug delivery systems. Advanced Drug Delivery Reviews, 45, 89–121.
Khurana, S., Jain, N. K., & Bedi, P. M. (2013). Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers’ gel for meloxicam. Life Sciences, 93(21), 763–772.
International Conference on Harmonisation (ICH). (2003). Harmonised tripartite guideline on stability testing of new drug substances and products (ICH Q1A (R2)). Japan and USA: Expert Working Group.
World Health Organization (WHO). (2009). Stability testing of active pharmaceutical ingredients and finished pharmaceutical products. WHO Technical Report Series, No. 953. Geneva, Switzerland.
Khan, H., Ali, M., Ahuja, A., & Ali, J. (2010). Stability testing of pharmaceutical products: Comparison of stability testing guidelines. Current Pharmaceutical Analysis, 6, 142–150.
Azeem, A., Ahmad, F. J., Khar, R. K., & Talegaonkar, S. (2009). Nanocarrier for the transdermal delivery of an antiparkinsonian drug. AAPS PharmSciTech, 10, 1.